Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives.
The PI3K/AKT/mTOR signaling system is essential for controlling cell growth, survival, proliferation, and metabolism, rendering it a significant therapeutic target in cancer treatment. Dysregulation of this system is commonly reported in numerous cancers, facilitating tumor development and resistanc...
| Publicado en: | Pharmacy Practice (1886-3655) Vol. 24; no. 1; pp. 1 - 14 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas S.L.
Jan-Mar2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193552772&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 193552772 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1885642X 3EAU jtl: Pharmacy Practice (1886-3655) issn: 1885642X maglogo: N pubinfo: dt: Jan-Mar2026 vid: 24 iid: 1 pid: 36266 pub: Centro de Investigaciones y Publicaciones Farmaceuticas S.L. artinfo: ui: 193552772 193552772 193552772 10.18549/PharmPract.2026.1.3337 193552772 ppf: 1 ppct: 13 formats: fmt: @attributes: type: P tig: atl: Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives. aug: au: Al Anta, Tasneem Al Shehadat, Ola Taneera, Jalal Aleidi, Shereen M. Abuhelwa, Ahmad A. Alzoubi, Karem H. Semreen, Mohammad H. El-Huneidi, Waseem Abu-Gharbieh, Eman Bustanji, Yasser affil: Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box, 27272, United Arab Emirates sug: subj: Neoplasms Drug Therapy MTOR Inhibitors Metabolism Intracellular Signaling Peptides and Proteins Metabolism Antineoplastic Agents, Combined Pharmacodynamics Ovarian Neoplasms Pancreatic Neoplasms Drug Therapy Colorectal Neoplasms Drug Therapy Neoplasm Metastasis Drug Therapy Breast Neoplasms Prostatic Neoplasms Lung Neoplasms Chemotherapy, Cancer Drug Resistance, Neoplasm Neoplasm Recurrence, Local ab: The PI3K/AKT/mTOR signaling system is essential for controlling cell growth, survival, proliferation, and metabolism, rendering it a significant therapeutic target in cancer treatment. Dysregulation of this system is commonly reported in numerous cancers, facilitating tumor development and resistance to standard therapy. Dual inhibitors that concurrently target both Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR) provide a more thorough inhibition of this pathway, reducing the deficiencies of single-agent inhibitors and bypassing compensatory mechanisms that frequently result in therapeutic resistance. This review investigates the molecular basis of dual PI3K/mTOR inhibition, emphasizing its potential to improve cancer treatment effects. We provide a concise overview of the preclinical and clinical data that substantiates the efficacy of dual inhibitors in various malignancies, including breast, prostate, colorectal, pancreatic, ovarian, and lung cancers. Significant antitumor activity has been demonstrated by notable dual inhibitors when combined with chemotherapy or targeted agents. However, challenges such as resistance and toxicity persist. Additional research is required to refine dose protocols, optimize patient selection by biomarker identification, and investigate combination drugs to improve efficacy while reducing undesirable effects. The advancement of nanoformulations has demonstrated potential in enhancing medicine delivery and reducing systemic toxicity. Dual PI3K/mTOR inhibitors constitute a promising therapeutic strategy, providing significant enhancements in tailored cancer treatment, particularly for individuals with resistant or aggressive malignancies. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|